SLC6A3 and Parkinson disease: In fact, Tzoulis and colleagues showed that despite severe mitochondrial alteration and neuronal loss in substantia nigra pars compacta (valued by dopamine transporter imaging and PET), many POLG patients did not show signs of clinical parkinsonism, probably by compensation of other brain structures such as thalamus and cerebellum.